Navigation Links
Cantel Medical Reports a 109% Increase in Net Income - EPS of $0.25 vs. $0.12 for Quarter Ended April 30, 2009

LITTLE FALLS, N.J., June 4 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 109% increase in net income to $4,183,000, or $0.25 per diluted share, on a 3.5% increase in sales to a record $66,431,000 for the third quarter ended April 30, 2009. This compares with net income of $2,001,000, or $0.12 per diluted share (including costs of $0.03 related to the resignation of our former President), on sales of $64,178,000 for the third quarter ended April 30, 2008. For the nine months ended April 30, 2009, the Company reported an 85% increase in net income to $11,290,000, or $0.69 per diluted share (inclusive of $0.02 of expenses related to the relocation of its Dutch manufacturing operations to the United States), on a 4.4% increase in sales to $193,257,000. This compares with net income of $6,097,000, or $0.37 per diluted share (including costs of $0.03 related to the resignation of our former President), on sales of $185,093,000 for the nine months ended April 30, 2008.

Andrew Krakauer, Cantel's President and CEO stated, "We are very pleased to have delivered another quarter of substantial earnings growth and our strongest quarterly performance of the past few years despite the worldwide economic slowdown. Cantel demonstrated sales growth in all reporting segments except for an expected decline in lower margin dialysate concentrate shipments in our Dialysis segment."

Krakauer added, "While all our businesses performed well, operating income in our Endoscope Reprocessing, Dialysis, and Water Purification and Filtration units was substantially ahead of last year, aided by strong sales of consumables, including disinfectants, sterilants and an increase in service revenue. Additionally, the positive performance was helped by our active cost reduction and margin improvement programs, the effectiveness of price increases and reduced interest expenses."

Krakauer continued, "Although our businesses are not immune to the economic downturn, we remain focused on our strategies to grow and improve performance. In this economy, our competitive advantage is our leadership positions in several infection prevention and control markets, a quality reputation and strong brands. Further, we have proactively developed our business to where approximately 75% of our sales come from disposables and service, which are supported by a large installed base of equipment."

The Company further reported that its balance sheet at April 30, 2009 included current assets of $86,844,000, including cash of $22,328,000, a current ratio of 2.4:1, debt of $49,300,000, stockholders' equity of $177,862,000 and a ratio of funded debt to equity of .28:1. Krakauer stated, "The Company has a strong balance sheet and continues to generate significant cash. Our cash provided by operating activities for the quarter was $8,085,000. We have reduced our net debt position from the second quarter by 21% to $27 million."

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.

The Company will hold a conference call to discuss the results for the third quarter ended April 30, 2009 on Thursday, June 4, 2009 at 11:00 AM Eastern time. To participate in the conference call, dial 1-877-407-8035 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Thursday, June 4, 2009 at 2:00 PM through midnight on June 11, by dialing 1-877-660-6853 and using passcode #286 and conference ID #324315.

The call will be simultaneously broadcast live over the Internet on at A replay of the webcast will be available on Vcall for 30 days.

For further information, visit the Cantel website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

                           CANTEL MEDICAL CORP.
                   (In thousands, except per share data)

                                Three Months Ended  Nine Months Ended
                                     April 30,          April 30,
                                ------------------  -----------------
                                   2009     2008      2009      2008
                                   ----     ----      ----      ----

    Net sales                    $66,431  $64,178  $193,257  $185,093

    Cost of sales                 40,908   41,897   120,500   120,120
                                  ------   ------   -------   -------

    Gross profit                  25,523   22,281    72,757    64,973

      Selling                      7,984    7,190    22,326    20,815
      General and administrative   9,106    9,923    27,167    27,847
      Research and development     1,261      928     3,309     2,879
                                   -----      ---     -----     -----
    Total operating expenses      18,351   18,041    52,802    51,541
                                  ------   ------    ------    ------

    Income before interest
     and income taxes              7,172    4,240    19,955    13,432

    Interest expense                 588    1,185     2,013     3,662
    Interest income                  (24)     (97)     (132)     (394)
                                     ---      ---      ----      ----

    Income before income taxes     6,608    3,152    18,074    10,164

    Income taxes                   2,425    1,151     6,784     4,067
                                   -----    -----     -----     -----

    Net income                    $4,183   $2,001   $11,290    $6,097
                                  ======   ======   =======    ======

    Earnings per common share
     - diluted                     $0.25    $0.12     $0.69     $0.37
                                   =====    =====     =====     =====

    Weighted average shares
     - diluted                    16,544   16,349    16,434    16,355

                            CANTEL MEDICAL CORP.
                               (In thousands)

                                             April 30,  July 31,
                                               2009       2008
                                               ----       ----
         Current assets                      $86,844    $84,561
         Property and equipment, net          35,685     37,920
         Intangible assets                    36,824     41,254
         Goodwill                            112,187    113,958
         Other assets                          1,062      1,497
                                               -----      -----
                                            $272,602   $279,190
                                            ========   ========

            Liabilities and stockholders' equity

         Current portion of long-term debt    $9,500     $8,000
         Other current liabilities            26,821     30,922
         Long-term debt                       39,800     50,300
         Other long-term liabilities          18,619     21,256
         Stockholders' equity                177,862    168,712
                                             -------    -------
                                            $272,602   $279,190
                                            ========   ========


    Reconciliation of Earnings Before Interest, Taxes, Depreciation,
     Amortization and Stock-Based Compensation Expense ("EBITDAS")

    The reconciliation of EBITDAS with net income for the three and nine
     months ended April 30, 2009 and 2008, respectively, is as follows (in

                                          Three Months Ended Nine Months Ended
                                                April 30,        April 30,
                                          ------------------ -----------------
                                              2009    2008     2009     2008
                                              ----    ----     ----     ----

    Net income                               $4,183  $2,001  $11,290   $6,097

    Income taxes                              2,425   1,151    6,784    4,067
    Interest expense                            588   1,185    2,013    3,662
    Interest income                             (24)    (97)    (132)    (394)
    Depreciation                              1,562   1,515    4,637    4,490
    Amortization                              1,264   1,438    3,870    4,297
    Loss on disposal of fixed assets              -      31       22       80
                                                ---     ---      ---      ---

    EBITDA                                    9,998   7,224   28,484   22,299

    Stock-based compensation expense            784     489    1,829    1,483
                                                ---     ---    -----    -----

    EBITDAS                                 $10,782  $7,713  $30,313  $23,782
                                            =======  ======  =======  =======

EBITDAS is a measure of the Company's performance that is not required by, or presented in accordance with, Generally Accepted Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial measure defined by the Company as income before interest, taxes, depreciation, amortization and stock-based compensation expense. The Company believes EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment, has on the Company's net income. In particular, acquisitions have historically resulted in significant increases in amortization of intangible assets that reduced the Company's net income. Additionally, the Company regards EBITDAS as a useful measure of operating performance and cash flow before the effect of interest expense and complements operating income, net income and other GAAP financial performance measures. Generally, a non-GAAP financial measure is a numerical measure of a Company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. This measure, however, should be considered in addition to, and not as a substitute or superior to, net income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

SOURCE Cantel Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
2. Cantel Medical to Relocate Dutch Manufacturing Operations to the United States to Achieve Operating Savings
3. Cantel Medical Corp. to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
4. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008
5. Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008
6. Cantel Medical Corp. to Present at the 11th Annual Needham Growth Stock Conference
7. Cantel Medical Corp.s Medivators Group Gains FDA 510(k) Approval For Its Advantage(TM) Plus Endoscope Reprocessing System
8. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its Second Quarter Ended January 31, 2009
9. Cantel Medical Reports 75% Increase in Net Income - EPS of $0.23 vs. $0.13 for Quarter Ended January 31, 2009
10. Cantel Medical Corp. to Present at the 13th Annual Sidoti & Company Emerging Growth Institutional Investor Forum
11. Cantel Medical Corp. Names Andrew Krakauer as CEO and Announces Other Corporate Appointments
Post Your Comments:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
Breaking Medicine Technology: